Laboratory Lab results are too important to go anywhere else.

Fluvoxamine Level

Luvox®

Test Codes

ARUP #91234, Antrim #83029, EPIC: LAB6026, SOFT: XFLUV

Specimen Collection Criteria

Collect (preferred specimen): Two plain Red-top tubes.
Also acceptable: Two Lavender-top EDTA tubes.

Do not use Serum Separator Tubes.
Time of Collection: Trough, just prior to the next dose.

Physician Office/Draw Specimen Preparation

Centrifuge to separate serum or plasma from cells. Transfer serum or plasma to a plastic transport tube and refrigerate (2-8°C or 36-46°F).

Preparation for Courier Transport

Transport: 3.0 mL serum or plasma, refrigerated (2-8°C or 36-46°F). (Minimum: 1.2 mL)

Rejection Criteria

Serum Separator (SST) tubes.

Specimens not collected and processed as indicated.

In-Lab Processing

Centrifuge to separate serum or plasma from cells. Transfer serum or plasma to a plastic transport tube and refrigerate (2-8°C or 36-46°F).

Transport: 3.0 mL serum or plasma, refrigerated (2-8°C or 36-46°F). (Minimum: 1.2 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 14 days
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 6 months

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to ARUP Laboratories, Salt Lake City, UT, forwarded to National Medical Services (NMS), Willow Grove, PA.

Performed

Varies.
Results available in 4-11 days.

Reference Range

By report.

Test Methodology

Quantitative Gas Chromatography.

Interpretation

• Following oral dosing, fluvoxamine reaches a peak plasma concentration within approximately 2 to 8 hours. Steady state plasma levels are obtained after approximately 10 days of administration. (1)
• Although a linear relationship between fluvoxamine plasma levels and clinical response has been suggested, a therapeutic plasma range has not yet been established. (2)

Clinical Utility

Fluvoxamine (Luvox®) is used for the treatment of obsessive-compulsive disorders. It is a potent and selective serotonin reuptake inhibitor that has also shown effectiveness in treating depression and panic attacks. The FDA has initially approved its use for obsessive-compulsive disorders only.

Reference

1. Benfield P., and Ward A., Fluvoxamine A Review of Its Pharmacodynamic Properties and Therapeutic Efficacy in Depressive Illness, Drugs, 32 (1986) 313-334.
2. Olin B.R. (editor-in-chief), Drug Facts and Comparisons Monthly Update, Facts and Comparisons, Inc., St. Louis, MO, August 1991, p.799.
3. De Wilde, J.E.M, and Doogan DP, Fluvoxamine and Chlorimipramine in Endogenous Depression, Journal of Affective Disorders, 4 (1982) 249-259.

CPT Codes

80332, (alt G0480).

Contacts

Last Updated

10/10/2020